Seaport Therapeutics Prices Upsized IPO at Top of Range

Seaport Therapeutics Inc., a biotechnology company specializing in the development of treatments for anxiety and depression, has successfully completed its initial public offering, raising nearly $255 million. The company's entry into the public markets provides a significant capital injection to support its neuro-psychiatry pipeline. The offering saw strong investor appetite, leading the company to increase the volume of shares available to the public. Seaport ultimately sold 14.16 million shares, a notable increase from the 11.8 million shares originally planned in its regulatory filings. Shares were priced at $18 each, hitting the absolute ceiling of the company's marketed range of $16 to $18. This pricing suggests high confidence from institutional investors in the company's clinical-stage assets. The proceeds from the IPO are expected to fund the company's ongoing research and development efforts as it seeks to bring its antidepressant and anxiety medications through the clinical trial process. While the successful debut is a positive milestone, the company's future valuation will remain tied to the efficacy and regulatory approval of its drug candidates.